Ascletis doses first subject in Phase I solid tumour trial
According to the preclinical studies, ASC61 demonstrated having good safety and pharmacokinetic profiles in animal models.

According to the preclinical studies, ASC61 demonstrated having good safety and pharmacokinetic profiles in animal models.
The funding will support translational research and trials and will have a quick impact on bladder cancer therapies.
The two-part trial will analyse the safety, pharmacokinetics, optimal dosing and initial activity of JBI-778.
To be carried out at four centres in China, the trial will have dose-escalation and dose-expansion portions.
In the trial, Tecentriq’s subcutaneous formulation safety profile was in line with that of IV Tecentriq.
The company anticipates topline data from the trial in the fourth quarter of this year.
The Phase II bridging study will assess the safety, pharmacokinetics, and efficacy of tazemetostat to treat R/R FL patients.
Companies are exploring ways to increase tumour visibility so more patients benefit from immune checkpoint inhibitor therapy.
ByThank you for subscribing to Clinical Trials Arena